A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507703-63-00

Acronym

LOXO-RET-18036

Enrollment

Registered

2024-06-18

Start date

2020-05-04

Completion date

Unknown

Last updated

2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Brief summary

PHASE 1 Frequency, severity and relatedness of TEAEs and SAEs, including DLTs in pediatric patients receiving selpercatinib, PHASE 2 ORR based on RECIST v 1.1 or RANO as appropriate to tumor type as determined by an IRC

Interventions

DRUGSELPERCATINIB

DRUGSelpercatinib

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
PHASE 1 Frequency, severity and relatedness of TEAEs and SAEs, including DLTs in pediatric patients receiving selpercatinib, PHASE 2 ORR based on RECIST v 1.1 or RANO as appropriate to tumor type as determined by an IRC	—

Countries

Denmark, France, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026